Foster Dykema Cabot & Partners, LLC Vertex Pharmaceuticals Inc Transaction History
Foster Dykema Cabot & Partners, LLC
- $1.12 Trillion
- Q2 2024
A detailed history of Foster Dykema Cabot & Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Foster Dykema Cabot & Partners, LLC holds 59,975 shares of VRTX stock, worth $29.2 Million. This represents 2.51% of its overall portfolio holdings.
Number of Shares
59,975
Previous 59,725
0.42%
Holding current value
$29.2 Million
Previous $25 Billion
12.6%
% of portfolio
2.51%
Previous 2.33%
Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,705Shares Held
226MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$13 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.2 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.4 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.7 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.15 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $125B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...